Anti-CD30 monoclonal antibody BerH2

Drug Profile

Anti-CD30 monoclonal antibody BerH2

Alternative Names: BerH2 antibody

Latest Information Update: 05 Sep 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medac; Nonindustrial sources
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hodgkin's disease

Most Recent Events

  • 30 Nov 1999 Antibody development agreement signed with Medarex
  • 16 Dec 1998 New profile
  • 16 Dec 1998 Phase-I clinical trials for Hodgkin's disease in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top